Lykins brings over 25 years of psychiatry and neuroscience-focused pharmaceutical launch experience across multiple organizations recognized as leaders in developing and commercializing medicines for central nervous system disorders, including Eli Lilly (NYSE: LLY), Lundbeck, Sunovion and Adadia Pharmaceuticals.
Lykins most recently served as the senior vice president, Global Product Planning and chief marketing officer for Adadia, where she oversaw their healthcare professional and consumer marketing, marketing operations and new product planning functions.
Prior to Adadia, she led commercialization and planning efforts for Lundbeck's portfolio of schizophrenia treatments from early development through commercialization.
Her US and global commercialization and strategic planning experience consists of 10 product launches, including Rexulti in schizophrenia, depression, and agitation in Alzheimer's disease, Ablify Maintena in schizophrenia and bipolar disorder, Latuda, Cymbalta, and Zyprexa, among other medicines representing first-in-class therapies for psychiatric and neurological conditions.
Lykins received her MBA with an emphasis in international business from University of South Carolina and received her B.A. in chemistry and honors humanities from Ball State University.
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference